Literature DB >> 33716709

Resilience to Plasma and Cerebrospinal Fluid Amyloid-β in Cognitively Normal Individuals: Findings From Two Cohort Studies.

Li Lin1, Yu Sun1, Xiaoqi Wang1, Li Su2, Xiaoni Wang1, Ying Han1,3,4.   

Abstract

Objective: To define resilience metrics for cognitive decline based on plasma and cerebrospinal fluid (CSF) amyloid-β (Aβ) and examine the demographic, genetic, and neuroimaging factors associated with interindividual differences among metrics of resilience and to demonstrate the ability of such metrics to predict the diagnostic conversion to mild cognitive impairment (MCI). <br> Methods: In this study, cognitively normal (CN) participants with Aβ-positive were included from the Sino Longitudinal Study on Cognitive Decline (SILCODE, n = 100) and Alzheimer's Disease Neuroimaging Initiative (ADNI, n = 144). Using a latent variable model of data, metrics of resilience [brain resilience (BR), cognitive resilience (CR), and global resilience (GR)] were defined based on the plasma Aβ and CSF Aβ. Linear regression analyses were applied to investigate the association between characteristics of individuals (age, sex, educational level, genetic, and neuroimaging factors) and their resilience. The plausibility of these metrics was tested using linear mixed-effects models and Cox regression models in longitudinal analyses. We also compared the effectiveness of these metrics with conventional metrics in predicting the clinical progression. <br> Results: Although individuals in the ADNI cohort were older (74.68 [5.65] vs. 65.38 [4.66], p < 0.001) and had higher educational levels (16.3 [2.6] vs. 12.6 [2.8], p < 0.001) than those in the SILCODE cohort, similar loadings between resilience and its indicators were found within both models. BR and GR were mainly associated with age, women, and brain volume in both cohorts. Prediction models showed that higher CR and GR were related to better cognitive performance, and specifically, all types of resilience to CSF Aβ could predict longitudinal cognitive decline. <br> Conclusion: Different phenotypes of resilience depending on cognition and brain volumes were associated with different factors. Such comprehensive resilience provided insight into the mechanisms of susceptibility for Alzheimer's disease (AD) at the individual level, and interindividual differences in resilience had the potential to predict the disease progression in CN people.
Copyright © 2021 Lin, Sun, Wang, Su, Wang and Han.

Entities:  

Keywords:  Alzheimer's disease; amyloid; cognitive decline; cognitively normal; resilience

Year:  2021        PMID: 33716709      PMCID: PMC7943465          DOI: 10.3389/fnagi.2021.610755

Source DB:  PubMed          Journal:  Front Aging Neurosci        ISSN: 1663-4365            Impact factor:   5.750


  44 in total

1.  Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease.

Authors:  David A Wolk; Bradford C Dickerson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

2.  Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease.

Authors:  Elizabeth C Mormino; Rebecca A Betensky; Trey Hedden; Aaron P Schultz; Andrew Ward; Willem Huijbers; Dorene M Rentz; Keith A Johnson; Reisa A Sperling
Journal:  Neurology       Date:  2014-04-18       Impact factor: 9.910

3.  Cognitive reserve and cortical thickness in preclinical Alzheimer's disease.

Authors:  Corinne Pettigrew; Anja Soldan; Yuxin Zhu; Mei-Cheng Wang; Timothy Brown; Michael Miller; Marilyn Albert
Journal:  Brain Imaging Behav       Date:  2017-04       Impact factor: 3.978

4.  Effect of cognitive reserve markers on Alzheimer pathologic progression.

Authors:  Raymond Y Lo; William J Jagust
Journal:  Alzheimer Dis Assoc Disord       Date:  2013 Oct-Dec       Impact factor: 2.703

5.  Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers.

Authors:  Olivier Hanon; Jean-Sébastien Vidal; Sylvain Lehmann; Stéphanie Bombois; Bernadette Allinquant; Jean-Marc Tréluyer; Patrick Gelé; Christine Delmaire; Fredéric Blanc; Jean-François Mangin; Luc Buée; Jacques Touchon; Jacques Hugon; Bruno Vellas; Evelyne Galbrun; Athanase Benetos; Gilles Berrut; Elèna Paillaud; David Wallon; Giovanni Castelnovo; Lisette Volpe-Gillot; Marc Paccalin; Philippe-Henri Robert; Olivier Godefroy; Thierry Dantoine; Vincent Camus; Joël Belmin; Pierre Vandel; Jean-Luc Novella; Emmanuelle Duron; Anne-Sophie Rigaud; Suzanna Schraen-Maschke; Audrey Gabelle
Journal:  Alzheimers Dement       Date:  2018-02-17       Impact factor: 21.566

6.  Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework.

Authors:  Clifford R Jack; Terry M Therneau; Stephen D Weigand; Heather J Wiste; David S Knopman; Prashanthi Vemuri; Val J Lowe; Michelle M Mielke; Rosebud O Roberts; Mary M Machulda; Jonathan Graff-Radford; David T Jones; Christopher G Schwarz; Jeffrey L Gunter; Matthew L Senjem; Walter A Rocca; Ronald C Petersen
Journal:  JAMA Neurol       Date:  2019-07-15       Impact factor: 18.302

7.  Sino Longitudinal Study on Cognitive Decline (SILCODE): protocol for a Chinese longitudinal observational study to develop risk prediction models of conversion to mild cognitive impairment in individuals with subjective cognitive decline.

Authors:  Xuanyu Li; Xiaoni Wang; Li Su; Xiaochen Hu; Ying Han
Journal:  BMJ Open       Date:  2019-07-26       Impact factor: 2.692

8.  Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship.

Authors:  Anna Catharina van Loenhoud; Wiesje Maria van der Flier; Alle Meije Wink; Ellen Dicks; Colin Groot; Jos Twisk; Frederik Barkhof; Philip Scheltens; Rik Ossenkoppele
Journal:  Neurology       Date:  2019-07-02       Impact factor: 9.910

9.  High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.

Authors:  Suzanne E Schindler; James G Bollinger; Vitaliy Ovod; Kwasi G Mawuenyega; Yan Li; Brian A Gordon; David M Holtzman; John C Morris; Tammie L S Benzinger; Chengjie Xiong; Anne M Fagan; Randall J Bateman
Journal:  Neurology       Date:  2019-08-01       Impact factor: 11.800

10.  Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition.

Authors:  Shannon L Risacher; Noelia Fandos; Judith Romero; Ian Sherriff; Pedro Pesini; Andrew J Saykin; Liana G Apostolova
Journal:  Alzheimers Dement (Amst)       Date:  2019-07-26
View more
  2 in total

Review 1.  Translational approaches to understanding resilience to Alzheimer's disease.

Authors:  Sarah M Neuner; Maria Telpoukhovskaia; Vilas Menon; Kristen M S O'Connell; Timothy J Hohman; Catherine C Kaczorowski
Journal:  Trends Neurosci       Date:  2022-03-17       Impact factor: 16.978

Review 2.  Oral microbiota in human systematic diseases.

Authors:  Xian Peng; Lei Cheng; Yong You; Chengwei Tang; Biao Ren; Yuqing Li; Xin Xu; Xuedong Zhou
Journal:  Int J Oral Sci       Date:  2022-03-02       Impact factor: 24.897

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.